Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 6/2005

01-11-2005 | Review Article

Peroxisome Proliferator-Activated Receptor-β and its Agonists in Hypertension and Atherosclerosis

Mechanisms and Clinical Implications

Authors: Carmen M. Halabi, Dr Curt D. Sigmund

Published in: American Journal of Cardiovascular Drugs | Issue 6/2005

Login to get access

Abstract

Cardiovascular diseases are the leading cause of morbidity and mortality in the US. Proper management and/ or prevention of atherosclerosis and hypertension, two complex and chronic disorders, would significantly reduce the risk for cardiovascular events such as myocardial infarction and stroke, but this requires an understanding of the mechanisms underlying their development and progression. Whereas a great deal has been learned and applied toward the management of these disorders, especially hypertension, morbidity and mortality remains unacceptably high, most likely because there are disease-causing mechanisms that have yet to be fully recognized. Understanding these disease mechanisms is necessary so that novel management strategies can be developed. One of these novel mechanisms centers on peroxisome proliferator-activated receptor (PPAR)-β. PPAR-β is a member of the nuclear receptor superfamily of ligand-activated transcription factors known to play a role in glucose homeostasis and adipocyte differentiation and, more recently, has been shown to have anti-inflammatory, antiatherogenic, and antihypertensive effects. Thiazolidinediones, a class of drugs used in the treatment of type 2 diabetes mellitus, are high-affinity ligands for PPAR-β. In this review, the anti-inflammatory, anti-atherosclerotic, and anti-hypertensive mechanisms by which PPAR-β and its agonists are thought to exert protective effects on the cardiovascular system are discussed. Ongoing clinical trials using PPAR-β activators for the management of cardiovascular diseases, especially in patients with type 2 diabetes mellitus, are summarized.
Literature
1.
2.
3.
Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347(6294): 645–50.PubMedCrossRef
4.
Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor β: implications for cardiovascular disease. Hypertension 2004; 43(2): 297–305.PubMedCrossRef
5.
Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94(9): 1168–78.PubMedCrossRef
6.
Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003; 27 Suppl. 3: S17–21.PubMedCrossRef
7.
Schiffrin EL, Amiri F, Benkirane K, et al. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42(4): 664–8.PubMedCrossRef
8.
Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68(5): 879–87.PubMedCrossRef
9.
Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994; 91(15): 7355–9.PubMedCrossRef
10.
Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60(8): 1245–50.PubMedCrossRef
11.
Puddu P, Puddu GM, Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int J Cardiol 2003; 90(2–3): 133–40.PubMedCrossRef
12.
Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferator-activated receptor (PPAR) a and PPARβ/6, but not PPARy, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003; 92(5): 518–24.PubMedCrossRef
13.
Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARβ gene. J Biol Chem 1997; 272(30): 18779–89.PubMedCrossRef
14.
Fajas L, Fruchart JC, Auwerx J. PPARβ3 mRNA: a distinct PPARβmRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438(1–2): 55–60.PubMedCrossRef
15.
Mukherjee R, Jow L, Croston GE, et al. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARβ2 versus PPARβl and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272(12): 8071–6.PubMedCrossRef
16.
Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-β (PPARy). J Biol Chem 1995; 270(22): 12953–6.PubMedCrossRef
17.
Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85(2–5): 267–73.PubMedCrossRef
18.
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord 2003; 27 Suppl. 3: S41–5.PubMedCrossRef
19.
Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20(11 Suppl. 2): II–10.PubMed
20.
21.
22.
Gimbrone MA, Resnick N, Nagel T, et al. Hemodynamics, endothelial gene expression, and atherogenesis. Ann N Y Acad Sci 1997; 811: 1–10.PubMedCrossRef
23.
Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76(2): 301–14.PubMedCrossRef
24.
Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89(3): 201–10.PubMedCrossRef
25.
Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol 1999; 84(1A): 15J–20J.PubMedCrossRef
26.
Inoue I, Shino K, Noji S, et al. Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246(2): 370–4.PubMedCrossRef
27.
Satoh H, Tsukamoto K, Hashimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARβ on vascular endothelial function. Biochem Biophys Res Commun 1999; 254(3): 757–63.PubMedCrossRef
28.
Law RE, Goetze S, Xi XP, et al. Expression and function of PPARβ in rat and human vascular smooth muscle cells. Circulation 2000; 101(11): 1311–8.PubMedCrossRef
29.
Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARβ: differentiation-dependent peroxisomal proliferator-activated receptor-β (PPARβ) expression and reduction of MMP-9 activity through PPARβ activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153(1): 17–23.PubMedCrossRef
30.
Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor-β (PPARβ) agonists. PPARβ co-association with transcription factor NFAT. J Biol Chem 2000; 275(7): 4541–4.PubMedCrossRef
31.
Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor-β (PPARβ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95(13): 7614–9.PubMedCrossRef
32.
Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21(3): 372–7.PubMedCrossRef
33.
Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21(3): 365–71.PubMedCrossRef
34.
Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-β agonist in hypercholesterolemia. Circulation 2003; 108(22): 2805–11.PubMedCrossRef
35.
Cho DH, Choi YJ, Jo SA, et al. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) β-dependent and PPARβ-independent signaling pathways. J Biol Chem 2004; 279(4): 2499–506.PubMedCrossRef
36.
Chinetti G, Lestavel S, Bocher V, et al. PPAR-α and PPAR-β activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAl pathway. Nat Med 2001; 7(1): 53–8.PubMedCrossRef
37.
Chawla A, Boisvert WA, Lee CH, et al. A PPAR β-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7(1): 161–71.PubMedCrossRef
38.
Akiyama TE, Sakai S, Lambert G, et al. Conditional disruption of the peroxisome proliferator-activated receptor β gene in mice results in lowered expression of ABCAl, ABCGl, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22(8): 2607–19.PubMedCrossRef
39.
Tontonoz P, Nagy L, Alvarez JG, et al. PPARβ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93(2): 241–52.PubMedCrossRef
40.
Liang CP, Han S, Okamoto H, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004; 113(5): 764–73.PubMed
41.
Argmann CA, Sawyez CG, McNeil CJ, et al. Activation of peroxisome proliferator-activated receptor β and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins. Arterioscler Thromb Vasc Biol 2003; 23(3): 475–82.PubMedCrossRef
42.
Jiang C, Ting AT, Seed B. PPAR-β agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391(6662): 82–6.PubMedCrossRef
43.
Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-β activators inhibit IFN-β-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164(12): 6503–8.PubMed
44.
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106(6): 679–84.PubMedCrossRef
45.
Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR β-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23(2): 283–8.PubMedCrossRef
46.
Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19(9): 2094–104.PubMedCrossRef
47.
Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-y activators. Circulation 2000; 101(3): 235–8.PubMedCrossRef
48.
Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40(5): 687–93.PubMedCrossRef
49.
Wakino S, Kintscher U, Kim S, et al. Peroxisome proliferator-activated receptor-β ligands inhibit retinoblastoma phosphorylation and G1→ S transition in vascular smooth muscle cells. J Biol Chem 2000; 275(29): 22435–41.PubMedCrossRef
50.
Marx N, Schonbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor-y activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83(11): 1097–103.PubMedCrossRef
51.
Hong HK, Cho YM, Park KH, et al. Peroxisome proliferator-activated receptor-β mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. Diabetes Res Clin Pract 2003; 62(1): 1–8.PubMedCrossRef
52.
Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86(7): 3452–6.PubMedCrossRef
53.
Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-β agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42(10): 1757–63.PubMedCrossRef
54.
Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24(5): 930–4.PubMedCrossRef
55.
Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4): 1381–478.PubMedCrossRef
56.
57.
Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42(6): 1075–81.PubMedCrossRef
58.
Takata Y, Kitami Y, Yang ZH, et al. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-β. Circ Res 2002; 91(5): 427–33.PubMedCrossRef
59.
Tannock LR, Little PJ, Tsoi C, et al. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 2004; 47(5): 837–43.PubMedCrossRef
60.
Eto K, Ohya Y, Nakamura Y, et al. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 2001; 423(1): 1–7.PubMedCrossRef
61.
Nakamura Y, Ohya Y, Onaka U, et al. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 1998; 123(4): 675–82.PubMedCrossRef
62.
Wu SN, Ho LL, Li HF, et al. Regulation of Ca (2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells. J Investig Med 2000; 48(4): 259–69.PubMed
63.
Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8(3): 316–20.PubMedCrossRef
64.
Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemie benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 1997; 46(3): 433–9.PubMedCrossRef
65.
Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331(18): 1188–93.PubMedCrossRef
66.
Negro R, Dazzi D, Hassan H, et al. Pioglitazone reduces blood pressure in nondipping diabetic patients. Minerva Endocrinol 2004; 29(1): 11–7.PubMed
67.
Gerber P, Lubben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003; 19(6): 532–9.PubMedCrossRef
68.
Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21(5): 415–22.PubMedCrossRef
69.
70.
Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-β. Circulation 2002; 105(19): 2296–302.PubMedCrossRef
71.
Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor-α and -β activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23(1): 45–51.PubMedCrossRef
72.
Ryan MJ, Didion SP, Mathur S, et al. PPAR (β) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43(3): 661–6.PubMedCrossRef
73.
Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor β ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23(1): 52–7.PubMedCrossRef
74.
Fukunaga Y, Itoh H, Doi K, et al. Thiazolidinediones, peroxisome proliferatoractivated receptor β agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001; 158(1): 113–9.PubMedCrossRef
75.
Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thronibin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85(5): 394–402.PubMedCrossRef
76.
Sugawara A, Takeuchi K, Uruno A, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-β in vascular smooth muscle cells. Endocrinology 2001; 142(7): 3125–34.PubMedCrossRef
77.
Song J, Walsh MF, Igwe R, et al. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes 1997; 46(4): 659–64.PubMedCrossRef
78.
Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARβ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402(6764): 880–3.PubMed
79.
Savage DB, Agostini M, Barroso I, et al. Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 2002; 31(4): 379–84.PubMed
80.
Tsai YS, Kim HJ, Takahashi N, et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARβ. J Clin Invest 2004; 114(2): 240–9.PubMed
81.
Barak Y, Nelson MC, Ong ES, et al. PPAR β is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4(4): 585–95.PubMedCrossRef
82.
Kubota N, Terauchi Y, Miki H, et al. PPAR β mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4(4): 597–609.PubMedCrossRef
83.
He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferatoractivated receptor β knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 2003; 100(26): 15712–7.PubMedCrossRef
84.
Norris AW, Chen L, Fisher SJ, et al. Muscle-specific PPARβ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112(4): 608–18.PubMed
85.
Hevener AL, He W, Barak Y, et al. Muscle-specific PPARβ deletion causes insulin resistance. Nat Med 2003; 9(12): 1491–7.PubMedCrossRef
86.
Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004; 93(HA): 27C–31C.PubMedCrossRef
87.
Gilling L, Suwattee P, DeSouza C, et al. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs 2002; 2(3): 149–56.PubMedCrossRef
88.
McDonnell DP. Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen. J Soc Gynecol Investig 2000; 7(1 Suppl.): S10–5.PubMedCrossRef
89.
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARβ-modulating activity. Hypertension 2004; 43(5): 993–1002.PubMedCrossRef
90.
Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-y activity. Circulation 2004; 109(17): 2054–7.PubMedCrossRef
91.
Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR α PPAR β agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 2003; 140(3): 527–37.PubMedCrossRef
92.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004; 26(7): 587–612.PubMed
93.
Keen HL, Ryan MJ, Beyer A, et al. Gene expression profiling of potential PPARβ target genes in mouse aorta. Physiol Genomics 2004; 18(1): 33–42.PubMedCrossRef
Metadata
Title
Peroxisome Proliferator-Activated Receptor-β and its Agonists in Hypertension and Atherosclerosis
Mechanisms and Clinical Implications
Authors
Carmen M. Halabi
Dr Curt D. Sigmund
Publication date
01-11-2005
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 6/2005
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200505060-00006

Other articles of this Issue 6/2005

American Journal of Cardiovascular Drugs 6/2005 Go to the issue

Review Article

Pharmacological Prevention of Venous Thromboembolism in Medical Patients at Risk

Review Article

Beyond Low-Density Lipoprotein

Review Article

The Role of the Platelet in the Pathogenesis of Atherothrombosis

Review Article

Antiarrhythmic Drugs in Patients with Implantable Cardioverter-Defibrillators

Therapy In Practice

Pharmacological Management of Atrial Fibrillation following Cardiac Surgery

Acknowledgments

Acknowledgment

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits